ACHN - アキリオン・ファ―マシュ―ティカルズ (Achillion Pharmaceuticals Inc.) アキリオン・ファ―マシュ―ティカルズ

 ACHNのチャート


 ACHNの企業情報

symbol ACHN
会社名 Achillion Pharmaceuticals Inc (アキリオン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アーキリオン・ファーマシューティカルズ(Achillion Pharmaceuticals Inc.)は生物医薬品企業である。同社は感染症と免疫系疾患の小分子薬物療法の発見および開発に従事する。同社は補体系の代替経路に関連する免疫関連疾患の治療に使用される小分子化合物の進歩を目的とした補体阻害剤プラットフォームに焦点を当てる。補体系は、ヒト先天性免疫系の一部である。補体阻害剤プラットフォームからの臨床化合物はACH-4471である。ACH-4471は、第I相臨床試験においてヒト健康なボランティアにおいて補体代替経路の阻害を示した因子Dの特異的阻害剤である。同社は、C型肝炎ウイルス(HCV)プログラムにおいて、ソバプレスビル、オダラビル、ACH-3422を含む複数の化合物の臨床開発・発見を行う。   アキリオン・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。感染症の治療の発見、開発、商業化に注力する。主に、慢性C型肝炎感染(HCV)の治療法の開発に焦点を当てる。HCV治療のための同社の薬物候補は、ACH-3102、NS5A阻害剤など。また同社は、HCVプロテア―ゼプログラムで、臨床候補ソバプレビルとACH-2684を発見した。   Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.
本社所在地 300 George Street New Haven CT 06511 USA
代表者氏名 David I. Scheer デイヴィッド・I・シェアー
代表者役職名 Independent Chairman of the Board
電話番号 +1 203-624-7000
設立年月日 36008
市場名 NASDAQ National Market System
ipoyear 2006年
従業員数
url www.achillion.com
nasdaq_url https://www.nasdaq.com/symbol/achn
adr_tso
EBITDA EBITDA(百万ドル) -82.23700
終値(lastsale) 3.44
時価総額(marketcap) 476736080.8
時価総額 時価総額(百万ドル) 453.17650
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 166.63750
当期純利益 当期純利益(百万ドル) -80.32800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Achillion Pharmaceuticals Inc. revenues was not reported. Net loss decreased 11% to $37.8M. Lower net loss reflects Outsourced research and supplies decrease of 33% to $11.9M (expense) Stock-based Compensation in R&D decrease of 46% to $1.5M (expense) Personnel costs in R&D decrease of 13% to $7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.31 to -$0.27.

 ACHNのテクニカル分析


 ACHNのニュース

   The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics  2020/01/28 12:12:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Vaccinex Inc (NASDAQ: VCNX ) Vir Biotechnology Inc (NASDAQ: VIR ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 27) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Correvio Pharma Corp (NASDAQ: CORV ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Heat Biologics Inc (NASDAQ: HTBX ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) MediciNova, Inc.
   Achillion Reports Positive Data from Phase 2 Study of Danicopan  2019/12/09 16:59:03 Investing News Network
The company announced results at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The post Achillion Reports Positive Data from Phase 2 Study of Danicopan appeared first on Investing News Network .
   Why Is Achillion (ACHN) Down 2.8% Since Last Earnings Report?  2019/12/07 16:31:15 Zacks Investment Research
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.  2019/11/30 04:30:00 GlobeNewswire
WILMINGTON, Del., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action…
   Brokerages Set Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) PT at $4.96  2019/11/16 01:41:59 Modern Readers
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has earned an average recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among […]
   The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics  2020/01/28 12:12:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Vaccinex Inc (NASDAQ: VCNX ) Vir Biotechnology Inc (NASDAQ: VIR ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 27) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Correvio Pharma Corp (NASDAQ: CORV ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Heat Biologics Inc (NASDAQ: HTBX ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) MediciNova, Inc.
   Achillion Reports Positive Data from Phase 2 Study of Danicopan  2019/12/09 16:59:03 Investing News Network
The company announced results at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The post Achillion Reports Positive Data from Phase 2 Study of Danicopan appeared first on Investing News Network .
   Why Is Achillion (ACHN) Down 2.8% Since Last Earnings Report?  2019/12/07 16:31:15 Zacks Investment Research
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.  2019/11/30 04:30:00 GlobeNewswire
WILMINGTON, Del., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action…
   Brokerages Set Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) PT at $4.96  2019/11/16 01:41:59 Modern Readers
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has earned an average recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among […]
   The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics  2020/01/28 12:12:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Vaccinex Inc (NASDAQ: VCNX ) Vir Biotechnology Inc (NASDAQ: VIR ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 27) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Correvio Pharma Corp (NASDAQ: CORV ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Heat Biologics Inc (NASDAQ: HTBX ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) MediciNova, Inc.
   Achillion Reports Positive Data from Phase 2 Study of Danicopan  2019/12/09 16:59:03 Investing News Network
The company announced results at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The post Achillion Reports Positive Data from Phase 2 Study of Danicopan appeared first on Investing News Network .
   Why Is Achillion (ACHN) Down 2.8% Since Last Earnings Report?  2019/12/07 16:31:15 Zacks Investment Research
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.  2019/11/30 04:30:00 GlobeNewswire
WILMINGTON, Del., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action…
   Brokerages Set Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) PT at $4.96  2019/11/16 01:41:59 Modern Readers
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has earned an average recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アキリオン・ファ―マシュ―ティカルズ ACHN Achillion Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)